GHRH is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-22. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3.4 to 3.6 kDa | Depends on whether the affinity complex is attached |
| Appearance | White to off-white lyophilized powder | Freeze-dried solid, often in a sealed vial |
| Solubility | Soluble in water and aqueous buffers | Dissolution rate varies with pH and buffer salt |
| Typical storage | Below minus 20 degrees Celsius, dry and dark | Dissolved material is usually kept cold and used promptly |
| Common analytical methods | Reversed-phase HPLC and mass spectrometry | Peptide mapping and amino acid analysis add sequence detail |
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
=== Initial adoption === Due to the influence tire pressure has on vehicle safety and efficiency, tire-pressure monitoring (TPM) was adopted by the European market as an optional feature for luxury passenger vehicles in the 1980s. The first passenger vehicle to adopt TPM was the Porsche 959 in 1986, using a hollow spoke wheel system developed by PSK. In 1996 Renault used the Michelin PAX system for the Scenic and in 1999 PSA Peugeot Citroën decided to adopt TPM as a standard feature on the Peugeot 607. The following year (2000), Renault launched the Laguna II, the first high volume mid-size passenger vehicle in the world to be equipped with TPM as a standard feature. In the United States, TPM was introduced by General Motors for the 1991 model year for the Corvette in conjunction with Goodyear run-flat tires. The system uses sensors in the wheels and a driver display which can show tire pressure at any wheel, plus warnings for both high and low pressure. It has been standard on Corvettes ever since.
==== Pharmacodynamic study ==== Considering its wide use, especially for cryopreservation and in vitro assays, we evaluated biological effect of DMSO using these technological innovations. We exposed 3D cardiac and hepatic microtissues to medium with or without 0.1% DMSO and analyzed the transcriptome, proteome and DNA methylation profiles. In both tissue types, transcriptome analysis detected >2000 differentially expressed genes affecting similar biological processes, thereby indicating consistent cross-organ actions of DMSO.There are transcriptional, translational and epigenetic changes caused by low concentration DMSO, despite the lack of acute toxicity. This is more of a concern for molecular biology experiments, because human body react transcriptionally to exogenic substances which can be totally normal and benign. For comparison, ethanol produces transcriptional changes that cause metabolic disorder.
===== MeSH D08.811.682.047 – alcohol oxidoreductases ===== MeSH D08.811.682.047.050 – acetoin dehydrogenase MeSH D08.811.682.047.070 – alcohol dehydrogenase MeSH D08.811.682.047.150 – carbohydrate dehydrogenases MeSH D08.811.682.047.150.225 – fructuronate reductase MeSH D08.811.682.047.150.250 – galactose dehydrogenases MeSH D08.811.682.047.150.270 – glucose dehydrogenases MeSH D08.811.682.047.150.270.500 – glucose 1-dehydrogenase MeSH D08.811.682.047.150.300 – glucosephosphate dehydrogenase MeSH D08.811.682.047.150.600 – phosphogluconate dehydrogenase MeSH D08.811.682.047.150.650 – phosphoglycerate dehydrogenase MeSH D08.811.682.047.150.700 – sugar alcohol dehydrogenases MeSH D08.811.682.047.150.700.075 – aldehyde reductase MeSH D08.811.682.047.150.700.237 – d-xylulose reductase MeSH D08.811.682.047.150.700.400 – glycerolphosphate dehydrogenase MeSH D08.811.682.047.150.700.400.500 – glycerol-3-phosphate dehydrogenase (nad+) MeSH D08.811.682.047.150.700.437 – l-gulonolactone oxidase MeSH D08.811.682.047.150.700.475 – l-iditol 2-dehydrogenase MeSH D08.811.682.047.150.700.649 – mannitol dehydrogenase MeSH D08.811.682.047.150.900 – uridine diphosphate glucose dehydrogenase MeSH D08.811.682.047.180 – choline dehydrogenase MeSH D08.811.682.047.210 – galactose oxidase MeSH D08.811.682.047.239 – glucose oxidase MeSH D08.811.682.047.370 – homoserine dehydrogenase MeSH D08.811.682.047.370.060 – aspartokinase homoserine dehydrogenase MeSH D08.811.682.047.385 – 3-hydroxyacyl coa dehydrogenases MeSH D08.811.682.047.385.415 – hydroxymethylglutaryl coa reductases MeSH D08.811.682.047.385.415.250 – hydroxymethylglutaryl-coa reductases, nad-dependent MeSH D08.811.682.047.385.415.750 – hydroxymethylglutaryl-coa-reductases, nadp-dependent MeSH D08.811.682.047.393 – hydroxybutyrate dehydrogenase MeSH D08.811.682.047.428 – Hydroxyprostaglandin dehydrogenase MeSH D08.811.682.047.432 – hydroxypyruvate reductase MeSH D08.811.682.047.436 – hydroxysteroid dehydrogenases MeSH D08.811.682.047.436.174 – 11-beta-hydroxysteroid dehydrogenases MeSH D08.811.682.047.436.174.300 – 11-beta-hydroxysteroid dehydrogenase type 1 MeSH D08.811.682.047.436.174.600 – 11-beta-hydroxysteroid dehydrogenase type 2 MeSH D08.811.682.047.436.350 – 3-hydroxysteroid dehydrogenases MeSH D08.811.682.047.436.350.100 – 3alpha-hydroxysteroid dehydrogenase (B-specific) MeSH D08.811.682.047.436.350.150 – cholesterol oxidase MeSH D08.811.682.047.436.350.700 – progesterone reductase MeSH D08.811.682.047.436.375 – 17-hydroxysteroid dehydrogenases MeSH D08.811.682.047.436.375.280 – estradiol dehydrogenases MeSH D08.811.682.047.436.400 – 20-hydroxysteroid dehydrogenases MeSH D08.811.682.047.436.400.074 – 20alpha-hydroxysteroid dehydrogenase MeSH D08.811.682.047.436.400.150 – cortisone reductase MeSH D08.811.682.047.485 – imp dehydrogenase MeSH D08.811.682.047.497 – isocitrate dehydrogenase MeSH D08.811.682.047.500 – 3-isopropylmalate dehydrogenase MeSH D08.811.682.047.524 – ketol-acid reductoisomerase MeSH D08.811.682.047.551 – lactate dehydrogenases MeSH D08.811.682.047.551.249 – epsilon-crystallins MeSH D08.811.682.047.551.400 – l-lactate dehydrogenase MeSH D08.811.682.047.551.500 – l-lactate dehydrogenase (cytochrome) MeSH D08.811.682.047.605 – malate dehydrogenase MeSH D08.811.682.047.748 – malate dehydrogenase (nadp+) MeSH D08.811.682.047.892 – xanthine dehydrogenase MeSH D08.811.682.047.928 – xanthine oxidase
Sporting leagues in Hong Kong include Hong Kong Premier League, Hong Kong Premiership (rugby union), Hong Kong A1 Division Championship, and the Hong Kong Ice Hockey League. Famous local sporting clubs include Hong Kong Football Club, South China Athletic Association, Kitchee SC, and Hong Kong Eastern. Hong Kong sports have been described as "Club Life". Some clubs have documented their history thoroughly, while others have disappeared along with their past.
Nondeletion forms: These defects, in general, involve a single base-pair substitution or small insertions near or upstream of the HBB gene. Deletion forms: base-pair deletions of different sizes involving the HBB gene produce syndromes such as hereditary persistence of fetal hemoglobin syndrome. Mutations are characterized as (βo) if they prevent any formation of β globin chains, and mutations are characterized as (β+) if they allow some β globin chain formation to occur.
Sources: en.wikipedia.org
== Discovery == NAPE-PLD is an enzyme activity - a phospholipase, acting on phospholipids found in the cell membrane. It is not homology but the chemical outcome of its activity that classes it as phospholipase D. The enzymatic activity was discovered and characterized in a series of experiments culminating in the 2004 publication of a biochemical purification scheme from which peptide sequencing could be accomplished. Researchers homogenized (finely ground) hearts from 150 rats and subjected the resulting crude lysate to sucrose sedimentation at 105,000 x g to separate the cell membranes from the remainder of the cell. The integral membrane proteins were then solubilized using octyl glucoside and subjected to four column chromatography steps (HiTrap SP HP cation-exchange column, HiTrap Q anion-exchange column, HiTrap Blue affinity column, Bio-Gel HTP hydroxyapatite column). Each of these separates the different types of membrane proteins into different sample containers when the proteins are eluted from the column over time, and by measuring the activity of samples in each container it was possible to track which ones received the active enzyme. Measurement of the enzyme activity was done by thin layer chromatography of a radioactive substrate sensitive to the NAPE-PLD enzymatic activity: Cleavage of the substrate affected where it appeared on the plate when the radiation was detected on a bioimaging analyzer.
==== Reaction with protein amino groups ==== Hypochlorous acid reacts readily with amino acids that have amino group side-chains, with the chlorine from HClO displacing a hydrogen, resulting in an organic chloramine. Chlorinated amino acids rapidly decompose, but protein chloramines are longer-lived and retain some oxidative capacity. Thomas et al. concluded from their results that most organic chloramines decayed by internal rearrangement and that fewer available NH2 groups promoted attack on the peptide bond, resulting in cleavage of the protein. McKenna and Davies found that 10 mM or greater HClO is necessary to fragment proteins in vivo. Consistent with these results, it was later proposed that the chloramine undergoes a molecular rearrangement, releasing HCl and ammonia to form an aldehyde. The aldehyde group can further react with another amino group to form a Schiff base, causing cross-linking and aggregation of proteins.
Since u needs to be finite at r = 0, c1 = 0. The no slip boundary condition at the pipe wall requires that u = 0 at r = R (radius of the pipe), which yields c2 = GR2/4μ. Thus we have finally the following parabolic velocity profile:
== Actin in cells == Intracellular actin cytoskeletal assembly and disassembly are tightly regulated by cell signaling mechanisms. Many signal transduction systems use the actin cytoskeleton as a scaffold, holding them at or near the inner face of the peripheral membrane. This subcellular location allows immediate responsiveness to transmembrane receptor action and the resulting cascade of signal-processing enzymes. Because actin monomers must be recycled to sustain high rates of actin-based motility during chemotaxis, cell signalling is believed to activate cofilin, the actin-filament depolymerizing protein which binds to ADP-rich actin subunits nearest the filament's pointed-end and promotes filament fragmentation, with concomitant depolymerization in order to liberate actin monomers. In most animal cells, monomeric actin is bound to profilin and thymosin beta-4, both of which preferentially bind with one-to-one stoichiometry to ATP-containing monomers. Although thymosin beta-4 is strictly a monomer-sequestering protein, the behavior of profilin is far more complex. Profilin enhances the ability of monomers to assemble by stimulating the exchange of actin-bound ADP for solution-phase ATP to yield actin-ATP and ADP. Profilin is transferred to the leading edge by virtue of its PIP2 binding site, and it employs its poly-L-proline binding site to dock onto end-tracking proteins. Once bound, profilin-actin-ATP is loaded into the monomer-insertion site of actoclampin motors.
There are two dedicated Noma hospitals in Nigeria, the first and oldest of which is the Noma Children Hospital Sokoto, staffed by resident and visiting medical teams supported by Médecins Sans Frontières. Some of the staff are noma survivors. The second and more recently commissioned centre is the Noma Centre Abuja, fully funded and sponsored by the Noma Aid Nigeria Initiative, where holistic and compressive management of the Noma patients is given. The team consists of a resident medical and surgical team and visiting surgeons from Europe. In other countries, such as Ethiopia, international charities work in collaboration with the local health care system to provide complex reconstructive surgery which can give back facial functions such as eating, speaking, and smiling. Teams of volunteer medics coming from abroad are often needed to support the local capacity to address the most severe cases, which can be extremely challenging even for senior maxillofacial surgeons. On 10 June 2010, the work of such volunteer surgeons was featured in a UK BBC Two documentary presented by Ben Fogle, Make Me a New Face: Hope for Africa's Hidden Children.
Sources: en.wikipedia.org
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.
In common usage the name without the affinity complex is often equated with MOD GRF 1-29, a fragment carrying four stabilizing substitutions. Strictly speaking, the term originally referred to the albumin-binding version. The overlap in naming causes frequent ambiguity in both informal and technical writing.
Reversed-phase chromatography separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the molecular mass and detects modifications such as oxidation. Sequence-level checks rely on peptide mapping or amino acid analysis when stronger confirmation is needed.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.